Table 5.

Comparison between Premenopausal and Postmenopausal Patients.

	Premenopausal (n = 75)	Postmenopausal (n = 77)	P value
Age	46.1 ± 6.8	65.6 ± 9.7	< 0.01
Stage
Stage Ⅱ	31 (41%)	27 (35%)	0.51
Stage Ⅲ	44 (59%)	50 (65%)
Diameter
<5 cm	45	52	0.40
>5 cm	30	25
Lymph Node Metastasis
<3	45 (60%)	38 (49%)	0.20
≥4	30 (40%)	39 (51%)
NG
NG1, 2	32 (43%)	24 (31%)	0.18
NG3	43 (57%)	53 (67%)
Chemotherapy
Yes	70 (93%)	56 (73%)	<0.01
Neoadjuvant
Adjuvant
No	5 (7%)	21 (27%)
Postoperative Endocrine Therapy
Yes			Tamoxifen vs. Aromataze inhibitor < 0.01
(Tamoxifen)	72 (96%)	4 (5%)
(Anastrozole)	0	42 (55%)
(Letrozole)	2 (3%)	26 (34%)
(Exemestane)	0	4 (5%)
No	1 (1%)	1 (1%)
LH-RH agonist	10 (13%)	0	<0.07

NG, nuclear grade